ADAP - Adaptimmune to regain rights to cancer drug programs from GSK

2023-04-11 09:35:58 ET

• Adaptimmune Therapeutics ( NASDAQ: ADAP ) said it will regain rights to the PRAME and NY-ESO cell therapy programs from GSK ( NYSE: GSK ).
• Adaptimmune will receive an upfront payment plus milestone-based payments totaling £30M related to the transfer of the clinical trials for the NY-ESO targeted programs.
• The companies will transition materials and data related to the preclinical PRAME targeted TCR T-cell therapy program to Adaptimmune during 2023.
• The companies are targeting transfer of sponsorship for GSK IGNYTE-ESO clinical trial (NCT03967223) and long-term follow-up clinical trial (NCT03391778) during Q3 2023.
• The companies noted that all other clinical trials within the NY-ESO targeting program are already closed to enrollment and have already been or will soon be completed by GSK.
• "The return of these T-cell programs to Adaptimmune bolsters our pipeline and our leadership position in the field of engineered TCR T-cells for solid tumors," said Helen Tayton-Martin, chief business and strategy officer, Adaptimmune. "We will continue to evaluate the emerging data for the NY-ESO asset to determine next steps."

For further details see: